This trial is evaluating whether KRAS peptide vaccine will improve 4 primary outcomes and 3 secondary outcomes in patients with Cancer of Pancreas. Measurement will happen over the course of 5, 13, and 17 weeks.
This trial requires 25 total participants across 1 different treatment group
This trial involves a single treatment. KRAS Peptide Vaccine is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
Participation is compensated
You will be compensated for participating in this trial.
"The following are the important symptoms of cancer of the pancreas, for which patients need immediate evaluation and treatment:\n1. Abdominal pain\n2. Upper abdominal discomfort\n3. Abnormal bowel movements\n4. Weight loss\n5. Diarrhea\n6. Vomiting\n7. Constipation\n8. Lymphadenopathy (lymph node enlargement)\n\nPancreatic cancer is the fourth-most common cause of cancer death in Canada." - Anonymous Online Contributor
"Histology examination of pancreatic tumor biopsy sections has led to an understanding of the mechanisms of malignant growths in the pancreas. The most common causes of pancreatic carcinoma are chronic pancreatitis (chronic inflammation due to excessive secretion from acinar cells), pancreatic adenocarcinoma, and intraductal papillary mucinous neoplasms. Patients who have had endoscopic retrograde cholangiopancreatography (ERCP) should undergo repeat ERCP after 5 years to assess for remaining lesions. Patients with a positive result should undergo exploratory surgery for disease staging to determine whether adjuvant therapy is warranted." - Anonymous Online Contributor
"In 2018, there was little evidence supporting the use of [substance P] antagonists as an anti-inflammatory therapy for inflammatory bowel disease. This includes against ulcerative colitis and Crohn's disease; however, there were some benefits associated with the drug in treating irritable bowel syndrome (IBS) due to non-ulcerative IBS subtypes. Research suggests that smoking is associated with increased risk of [pancreatic cancer](https://www.withpower.com/clinical-trials/pancreatic-cancer). There is no evidence that [nonsteroidal anti-inflammatory drugs (NSAIDs)] increase the risk of pancreatic cancer. There is tentative evidence that [tinzaparin] may reduce risk of cancer of the pancreas." - Anonymous Online Contributor
"The risk of developing pancreatic cancer increases with age. Moreover, approximately 10% of all cases are diagnosed before the age of 40 years. Men and women younger than 40 years have about the same risk of developing pancreatic cancer. After the age of 60 years, however, women have a significantly increased risk compared to men. This difference can be attributed to higher rates of overweight and obesity among women." - Anonymous Online Contributor
"Sex-, race-, and ethnicity-adjusted average age at diagnosis of pancreatic cancer varies across racial groups within the United States. Race-specific average age at diagnosis differs according to sex and ethnicity. In a recent study, we found that men had a higher overall mean age at diagnosis than women and that African Americans had a younger median age at diagnosis than Caucasians." - Anonymous Online Contributor
"Although this vaccine has only recently been developed, we believe that the results presented here warrant further study on the CEA-specific vaccination approach. Further studies will need to be conducted to assess the long-term safety profile and tolerability of the approach investigated in this report." - Anonymous Online Contributor
"The Kras peptide vaccine was commonly combined with chemotherapy and/or radiotherapy in our study population. Results from a recent clinical trial suggest that the addition of immunotherapy to chemotherapy or radiotherapy may improve the survival rate of patients with pancreatic cancer. More prospective studies will be needed to confirm these results." - Anonymous Online Contributor
"Vaccine against ASPK peptide may provide protection against pancreatic cancer, also provides a good chance to stimulate antitumor immunity, and therefore has great potential value in treatment of pancreatic cancer." - Anonymous Online Contributor
"There have not been any new developments in the cancer of pancreas even though many types of pancreatic cancers do exist. However, there was an increase in detecting pancreatic cancer due to more frequent screenings and early diagnosis. This helps decrease mortality rates of this type of cancer. The importance of this is because pancreatic cancer is one of the few cancers where there is a high chance of being cured if detected early." - Anonymous Online Contributor
"It was concluded that there were some factors that increased the risk of developing Pancreas cancer. The main cause of pancreatic cancer is hereditary non-inherited pancreatic cancer (HNPCC), which is associated with genetic alterations in DNA repair pathways and endocrine cells. Other causes include age, sex, smoking, obesity, diabetes mellitus type 2 (DM2), alcohol consumption and familial adenomatous polyposis (FAP).\n\nIn India, pancreatic cancer is one of the most common types of cancers, accounting for 11% of all cancers in 2011. In 2012, it was found that pancreatic cancer had the highest mortality rate among all cancers in both men and women in India." - Anonymous Online Contributor
"Clinical trials provide an opportunity to understand the biology of pancreatic cancer and to evaluate the safety and efficacy of novel approaches. Patients with advanced pancreatic cancer should be considered for clinical trial enrollment." - Anonymous Online Contributor